Articles by K. Hariram, Pankaj Mehrotra, Rinkesh Shah, Gopal Kishore, Amaninder S. Dhillon, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal, and Mahendra Kumar Rai

Can Medicines Inject the Vitamins Amazon is Missing?

How Amazon’s Healthcare Bet May Change Indian Diagnostics and...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

Is Indian Pharma Singing Digital Without Lyrics?

A large part of the pharma houses continues to...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Marketing

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Policies/Sales

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Strategy

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Is Pharma Losing Good SalesPeople

Articles by Gopal Kishore, K. Hariram, Pankaj Mehrotra and Vivek Hattangadi

Violence Against Doctors: Doctor-Patient Relationship Bruised and Battered

If a business fails, it was an idea that didn’t work. If treatment fails – it must be a botch up. A broken gadget may be beyond repair, but not a patient in a doctor’s hands. From such ungraded expectations stems the potential for things to take an ugly turn. An unwanted profession dealing with an unwanted condition, namely Ill health: If possible, we would wish away death and diseases, hospitals and doctors. A hospital is not a holiday resort, but it too costs money. And the scenario of an adverse outcome like death simply becomes unacceptable.

Novo Nordisk to Acquire Akero Therapeutics for $4.7 Billion

Novo Nordisk has announced plans to acquire Akero Therapeutics...

Rx 2024 – Top 25 Drugs by Sales, Growth & Market Trends

The pharmaceutical market in 2024 saw major shifts driven...

Levamisole Withdrawn in EU: Will India’s Regulator Follow?

On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Marketing

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Policies/Sales

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Strategy

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Pawan V. Kulkarni

Pawan V. Kulkarni is the General Manager: Corporate Strategy at J B Chemicals and Pharmaceuticals Ltd.

What my Sabziwali taught me about the Internet, Mobile Health & Smartphones

Thought Leadership Pawan V. Kulkarni - December 16, 2018

It’s very common for a pharma professional having neighbors, friends and relatives to engage in conversation over medicines. One such conversation – a pleasant surprise – which intrigued me to dig deep into internet dynamics was one with the local roadside Sabziwali.